Article info
PDFAsthma
Original research
Genetic and T2 biomarkers linked to the efficacy of HDM sublingual immunotherapy in asthma
- Correspondence to Dr Peter Sejer Andersen, Translational Research, Alk-Abello A/S, Horsholm 2970, Denmark; petersejer.andersen{at}alk.net
Citation
Genetic and T2 biomarkers linked to the efficacy of HDM sublingual immunotherapy in asthma
Publication history
- Received July 13, 2023
- Accepted December 3, 2023
- First published December 30, 2023.
Online issue publication
March 15, 2024
Article Versions
- Previous version (30 December 2023).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.